Table 1 Characteristics of the study population
From: Clinical factors associated with severe hypophosphataemia after kidney transplant
Variable | All patients (n = 1838) | No. of missing values |
|---|---|---|
Epidemiological | ||
 Recipient sex (% Female) | 39.9% | 0 |
 Median age at transplant (years [IQR]) | 48 (37–57) | 0 |
 Donor sex (% Female) | 49.5% | 260 |
 Median donor age (years [IQR]) | 50 (39–59) | 282 |
 Transplant type (% deceased donor) | 73.8% | 0 |
Biochemical | ||
 Median pre-transplant phosphate (mmol/L [IQR]) | 1.64 (1.37–1.96) | 49 |
 Median pre-transplant adjusted calcium (mmol/L [IQR]) | 2.40 (2.29–2.50) | 172 |
 Median pre-transplant alkaline phosphatase (U/L [IQR]) | 108 (75–173) | 56 |
 Median pre-transplant PTH (xULN [IQR]) | 5.8 (3.0–10.1) | 53 |
 Median serum creatinine 7–10 days post-transplant (μmol/L [IQR]) | 212 (123–504) | 14 |
Clinical | ||
 Median duration of RRT pre-transplant (years [IQR]) | 1.93 (0.75–3.79) | 0 |
Modality of RRT prior to transplantation | 8 | |
 Haemodialysis | 58.9% |  |
 Peritoneal dialysis | 28.4% |  |
 None (pre-emptive transplantation) | 12.2% |  |
 Parathyroidectomy pre-transplant (%) | 9.7% | 0 |
 On alfacalcidol or calcitriol pre-transplant (%) | 55.2% | 0 |
 On cinacalcet pre-transplant (%) | 11.2% | 0 |
 Era of immunosuppression (% pre-01/01/2007) | 30.4% | 0 |
 Delayed graft function | 20.1% | 0 |